Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

K and apr-246: news just out today about the competition. Aprea announces $50 million funding raised for further trials for its p53 drug, to fund many other types of cancer trials beyond ovarian, and to establish a strategic US team- no details provided.

BUT Nota bene: good news in the business wire article. The randomized phase 2 trial is about to begin- they have been working on the 1b portion of PISARRO apparently, presumably establishing dosing. Even though this trial started 2 years ago, Aprea is only now at the stage where CTIX also is now- about to begin randomized P2.

Not bad news for CTIX I think, despite the competition.

The large question of course is: is K dosing optimized at this point? Is 3x week really just right? Will there be other dosing studied in the K ovarian P2 trial?

I still find it hard to believe that the dosing is dialed in yet. They have written about long infusion times versus shorter(given short half life) Will 5x week be better? Or a pump multiple days a week dosing over 8 or12 hrs? The company says it has gathered adequate pk data to decide dosing and we shall see- such critical choices to determine efficacy.

It would be great if we could see phase 2 results before Aprea ( yes I realize the drugs work differently, and K has multiple modes of action, and yes that is partly why I am a shareholder)- bragging rights first in class p53 drug- something Aprea claims for itself currently.